Abstract
Gluconeogenesis combats cancer: opening new doors in cancer biology.
Highlights
Research from our group has demonstrated a novel mechanism of cancer cell death by mTOR inhibitors, often used in hepatocellular (HCC) and renal cell carcinomas (RCC) therapy, by augmenting the gluconeogenesis pathway
Our results further suggest that upregulation of the gluconeogenic pathway creates a metabolic stress where bulk of the glucose is exported outside the cells creating a 'futile' cycle for glucose that in turn detrimentally affects the cell survival
It is imperative that concomitant activation or downregulation of glycolysis and gluconeogenesis would cause a metabolic stress, which might in turn disrupt the metabolic rewiring of cancer cells
Summary
Research from our group has demonstrated a novel mechanism of cancer cell death by mTOR (mechanistic target of rapamycin) inhibitors, often used in hepatocellular (HCC) and renal cell carcinomas (RCC) therapy, by augmenting the gluconeogenesis pathway. Our results further suggest that upregulation of the gluconeogenic pathway creates a metabolic stress where bulk of the glucose is exported outside the cells creating a 'futile' cycle for glucose that in turn detrimentally affects the cell survival.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
